📗 Cite This Artifact
Philippines Neurodegeneration Biotech Companies
Executive Summary
Executive Summary
The Philippines represents an emerging hub for neuroscience research and biotechnology innovation in Southeast Asia, with a growing ecosystem of pharmaceutical companies, biotechnology firms, and academic research institutions actively engaged in neurodegenerative disease research. The country's pharmaceutical sector, valued at approximately $3.5 billion, has seen increased investment in central nervous system (CNS) drug development targeting [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), driven by favorable government policies, expanding clinical trial infrastructure, and strong academic partnerships with international research institutions["@philippines_neuro_2023"].
The Philippine government, through the Department of Science and Technology (DOST), has prioritized biotechnology as a key growth sector, implementing policies that encourage local drug development and reduce dependence on imported pharmaceuticals. This strategic focus has catalyzed the emergence of several domestic pharmaceutical companies with active neuroscience programs, alongside academic-medical centers that conduct cutting-edge research into neurodegenerative disease mechanisms relevant to the Filipino population["@biotech_policy"].
Pharmaceutical Companies
United Laboratories (Unilab Inc.)
Headquarters: Manila, Philippines Website: https://www.unilab.com.ph Founded: 1945 Employees: 5,000+
United Laboratories, commonly known as Unilab, is the largest pharmaceutical company in the Philippines, with a market share exceeding 30% of the domestic pharmaceutical market. Founded in 1945, the company has grown from a local drug distributor to a fully integrated pharmaceutical enterprise with manufacturing, research, and distribution capabilities spanning the archipelago[@pharma_trends].
Unilab's CNS division has developed a robust portfolio of medications for neurological disorders, including antiepileptic drugs, medications for Parkinson's disease management, and treatments for Alzheimer's disease symptoms. The company's research and development division, located in its Laguna manufacturing facility, has established collaborations with international pharmaceutical partners to develop novel therapeutics for neurodegenerative diseases[@unilab].
Research Programs:
- Alzheimer's Disease Program: Unilab has partnered with international biotechnology companies to develop acetylcholinesterase inhibitors and NMDA receptor antagonists for Alzheimer's disease treatment. The company conducts bioequivalence studies for generic versions of donepezil, rivastigmine, and memantine[@admet].
- Parkinson's Disease Program: Research collaborations with Japanese pharmaceutical companies have enabled development of dopaminergic agents and MAO-B inhibitors for Parkinson's disease management.
- Neuroprotection Research: Unilab's R&D division investigates natural product-derived compounds with neuroprotective properties, leveraging the Philippines' rich biodiversity of medicinal plants.
Unilab operates GMP-certified manufacturing facilities in Laguna and Cavite, producing both oral solid dosage forms and injectables. The company's quality systems comply with FDA Philippines and international regulatory standards.
iForte Inc.
Headquarters: Manila, Philippines Website: https://www.iforte.com.ph
iForte Inc. is a Filipino pharmaceutical company specializing in specialty pharmaceuticals, with particular focus on the central nervous system therapeutic area. The company has established itself as a key player in the Philippine CNS market, providing both locally-manufactured and imported specialty medications[@iforte].
Product Portfolio:
- Neurological disorder medications (epilepsy, Parkinson's disease)
- Alzheimer's disease symptomatic treatments
- Neuropsychiatric medications
- Specialty injectables for hospital use
iForte has entered into licensing agreements with European and Japanese pharmaceutical companies to distribute innovative CNS medications in the Philippines. The company serves as a critical link between international pharmaceutical innovation and Filipino patients requiring specialized neurological care.
Paxion Pharmaceuticals
Headquarters: Manila, Philippines
Paxion Pharmaceuticals is a domestic pharmaceutical company focused on developing treatments for central nervous system disorders. The company was founded with a specific mission to address the unmet medical needs in neurological diseases prevalent in the Filipino population.
Research Focus:
- Development of novel anticonvulsant agents
- Parkinson's disease therapeutic development
- Neurodegenerative disease biomarkers
Paxion's research division collaborates with the University of the Philippines Manila's College of Medicine to conduct preclinical studies on potential neurotherapeutic compounds. The company's approach emphasizes understanding the genetic and environmental factors specific to the Southeast Asian population that may influence neurodegenerative disease progression and treatment response.
Flora Biotech Inc.
Headquarters: Manila, Philippines
Flora Biotech Inc. is a biotechnology company developing biologics and novel therapeutic modalities for treatment of neurological disorders. The company leverages advanced recombinant DNA technology and protein engineering to create next-generation biologics.
Technology Platform:
- Recombinant protein production
- Antibody engineering
- Cell-based therapy development
Flora Biotech's neuroscience pipeline includes development of neurotrophic factors and recombinant proteins targeting neurodegenerative pathways. The company has established partnerships with academic institutions in the Philippines and abroad to advance its therapeutic candidates through preclinical development.
JG Summit Petrochemical Corporation (Pharma Division)
Headquarters: Manila, Philippines
JG Summit, one of the Philippines' largest conglomerates, maintains a pharmaceutical division focused on specialty pharmaceuticals, including CNS medications. The company has invested significantly in building local R&D capabilities for drug development.
Focus Areas:
- CNS disorder treatments
- Specialty hospital products
- Generic pharmaceutical products
MedChoice Pharma Inc.
Headquarters: Manila, Philippines
MedChoice Pharma is a Filipino pharmaceutical company with a growing portfolio in neurology and psychiatry medications. The company has expanded its CNS portfolio through both organic development and strategic partnerships.
Products:
- Antiepileptic medications
- Parkinson's disease treatments
- Alzheimer's disease medications
- Psychiatric pharmaceuticals
Euro-Care Inc.
Headquarters: Manila, Philippines
Euro-Care Inc. focuses on specialty pharmaceuticals, with a significant presence in the CNS therapeutic area. The company imports and distributes European pharmaceutical products while developing local generic alternatives.
Healthcare and Research Institutions
University of the Philippines - Manila
Location: Manila, Philippines Website: https://www.upm.edu.ph
The University of the Philippines Manila (UP Manila) serves as the premier research university in the Philippines, with a strong focus on health sciences research. The university's neuroscience research program is conducted through multiple departments and research centers[@upm].
Neuroscience Research Programs:
- Philippine Brain Research Center: Established with DOST funding, this center conducts fundamental research on neural development, function, and disease.
- Neurodegenerative Disease Research Group: Investigates the epidemiology, genetics, and treatment of Alzheimer's disease and Parkinson's disease in the Filipino population.
- Clinical Neurology Division: Conducts clinical research on neurological disorders, including participation in international clinical trials.
- Genetic Studies: UP Manila researchers have conducted studies on APOE gene variants in the Filipino population, identifying unique allele frequencies that may influence Alzheimer's disease risk[@apoe].
- Neuroepidemiology: Population-based studies on dementia prevalence and cognitive decline in Filipino elderly have provided critical data for healthcare planning[@cognitive_aging].
- Neuroimaging: Collaborative research with international partners has established neuroimaging protocols for early detection of neurodegenerative changes in Filipino patients.
Philippine Genome Center
Location: Quezon City, Philippines Website: https://pgc.up.edu.ph
The Philippine Genome Center (PGC), established by the University of the Philippines System, serves as the national center for genomic research. The center's programs include significant work on neurodegenerative disease genetics[@pgc].
Relevant Programs:
- Neurogenomics Program: Studies genetic factors contributing to neurodegenerative diseases in Filipino populations
- Population Genomics: Characterizes genetic diversity relevant to disease susceptibility and drug response
- Bioinformatics Core: Provides computational infrastructure for genomic data analysis
The PGC collaborates with international research consortia studying neurodegenerative disease genetics, contributing Filipino population data to global studies on Alzheimer's disease and Parkinson's disease risk factors.
Research Institute for Tropical Medicine
Location: Muntinlupa, Philippines Website: https://ritm.gov.ph
The Research Institute for Tropical Medicine (RITM) is a research institution under the Department of Health, focusing on infectious diseases and their neurological manifestations. While primarily known for infectious disease research, RITM has expanded into neuroscientific research[@ritm].
Relevant Research:
- Neurological complications of infectious diseases
- Neuroinflammation research
- Clinical trials for neurological medications
Government Policy and Support
Department of Science and Technology (DOST)
The Department of Science and Technology plays a pivotal role in supporting neuroscience research and biotechnology development in the Philippines[@dost].
Key Initiatives:
- Philippine Neuroscience Development Program: Funding for neuroscience research projects at universities and research institutions
- Biotechnology Program: Support for local biotech companies developing novel therapeutics
- Clinical Research Support: Infrastructure development for clinical trials including neurological disease studies
- Grants for neuroscience research through the Philippine Council for Health Research and Development (PCHRD)
- Technology transfer programs for pharmaceutical development
- Scholarship programs for neuroscience researchers
Regulatory Framework
The Philippines Food and Drug Administration (FDA Philippines) provides regulatory oversight for pharmaceutical research and development. The agency has implemented fast-track approval pathways for innovative medications addressing unmet medical needs, including neurodegenerative disease treatments[@clinical_trials_ph].
Recent Regulatory Developments:
- Expanded clinical trial licensing for CNS studies
- Accelerated approval pathway for Alzheimer's disease medications
- Generic drug approval reforms to increase accessibility
Research Focus Areas
Alzheimer's Disease Research
Research on Alzheimer's disease in the Philippines focuses on several key areas:
Parkinson's Disease Research
Parkinson's disease research in the Philippines addresses:
Neuroinflammation
Research on neuroinflammation in the Philippine context considers:
- Environmental factors unique to Southeast Asia
- Infectious disease-related neuroinflammation
- Genetic factors influencing inflammatory responses[@neuro_inflammation]
Academic and Industry Collaborations
International Partnerships
Philippine research institutions and companies maintain active collaborations with international partners:
- Japanese Collaborations: Partnerships with Japanese pharmaceutical companies and universities for neuroscience research
- US Collaborations: Research collaborations with US institutions including NIH and Alzheimer's disease research centers
- ASEAN Initiatives: Regional collaboration through ASEAN neuroscience research networks[@asean_neuro_2022]
Regional Networks
The Philippines participates in regional research networks:
- ASEAN Neuroscience Research Network: Collaborative research on neurodegenerative diseases across Southeast Asia
- Asia-Pacific Research Initiative: Regional studies on brain disorders
- Global Alzheimer's Association International Consortium: Contributing Filipino population data to global research efforts
Challenges and Opportunities
Current Challenges
Opportunities
Future Directions
The Philippine neuroscience and biotechnology sector is positioned for significant growth, with several initiatives underway:
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Biotechnology Companies](/companies)
- [Pharmaceutical Research](/companies)
External Links
- [Department of Science and Technology - Philippines](https://www.dost.gov.ph)
- [Philippine FDA](https://www.fda.gov.ph)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-philippines-neurodegeneration-biotech |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-b6f973f65338 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-philippines-neurodegeneration-biotech'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-philippines-neurodegeneration-biotech?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Philippines Neurodegeneration Biotech Companies](http://scidex.ai/artifact/wiki-companies-philippines-neurodegeneration-biotech)
http://scidex.ai/artifact/wiki-companies-philippines-neurodegeneration-biotech